Tackling Chronic Disease: Creating Value and Impact through Upstream Intervention

-

Life expectancy in the US fell by 2.26 years from 2019 to 2022, the biggest drop since WW II. COVID-19 accounts for 74 percent of the drop, but chronic conditionse.g., diabetes, heart disease, kidney diseasehave heavy health and economic costs. Of $4.1 trillion in US annual health expenditures, 90 percent goes to chronic conditions, including mental health. The numbers of US adults with diabetes and obesity are at epidemic levels. These conditions, along with COVID-19, are significantly increasing the prevalence of kidney disease. Population aging and lifestyle changes add to the increase, straining the health-care system. Trends are emerging toward upstream interventions using strategies to detect chronic diseases earlier and slow progression. Speakers will review trial approaches to improve population health and meet growing demands, e.g., for person-centered care and value-based payment models. They will discuss potential drivers of transformative change to modernize care, and clarify opportunities for reshaping chronic disease management. 

    Moderator

    Image

    Nicholas Florko

    Washington Correspondent, STAT

    Speakers

    Image

    Derek Asay

    Senior Vice-President, Lilly Value and Access, Eli Lilly and Company
    Image

    Arta Bakshandeh

    Chief Medical Informatics Officer, Alignment Health
    Image

    Matt Eyles

    CEO, America's Health Insurance Plans
    Image

    Donna Grande

    CEO, American College of Preventive Medicine
    Image

    Dora Hughes

    Chief Medical Officer, CMS Innovation Center, Centers for Medicare & Medicaid Services